Clinical trial
Gefitinib in Treating Patients With Previously Untreated Stage IIIB or Stage IV…
NCT00411047 · Massachusetts General Hospital, Other · Completed
Key facts
| NCT number | NCT00411047 |
|---|---|
| Title | Gefitinib in Treating Patients With Previously Untreated Stage IIIB or Stage IV Non-Small Cell Lung Cancer |
| Official title | A Phase II, Open Label Study of Gefitinib (IRESSA) in Treatment-Naïve Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer and Somatic Activating Mutations in the Epidermal Growth Factor Receptor |
| Lead sponsor | Massachusetts General Hospital, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | gefitinib |
| Enrollment | 34 |
| Start date | Sep 1, 2005 |
| Primary completion | Jan 1, 2007 |
| Completion | Dec 1, 2012 |
| First posted | Dec 13, 2006 |
| Last update posted | May 14, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: